Roche

OverviewSuggest Edit

Roche Holding is the holding company of F. Hoffmann-La Roche, a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics. The Pharmaceuticals segment offers products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, etc. The Diagnostics segment offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health.
TypePublic
Founded1896
HQBasel, CH
Websiteroche.com
Employee Ratings4.2
Overall CultureA-

Latest Updates

Employees (est.) (Dec 2021)100,920
Job Openings2,985
Revenue (FY, 2021)CHF62.8 B(+8%)
Share Price (Jun 2022)CHF319.6
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Roche

Severin Schwan

Severin Schwan

Chief Executive Officer Roche Group and Director
William N. Anderson

William N. Anderson

CEO Roche Pharmaceuticals
Thomas Schinecker

Thomas Schinecker

CEO Roche Diagnostics
Alan Hippe

Alan Hippe

Chief Financial & Information Officer
Cristina A. Wilbur

Cristina A. Wilbur

Chief People Officer
Claudia Böckstiegel

Claudia Böckstiegel

General Counsel
Show more

Roche Office Locations

Roche has offices in Basel, Risch-Rotkreuz, Rotkreuz ZG, Schlieren and in 113 other locations
Basel, CH (HQ)
124 Grenzacherstrasse
Basel, CH
Gartenstrasse 9
Basel, CH
Jacob-Burckhardt-Haus 4 Peter Merian-Weg 4
Risch-Rotkreuz, CH
Rischerstrasse
Rotkreuz ZG, CH
Forrenstrasse 2
Rotkreuz ZG, CH
Industriestrasse 7
Show all (147)

Roche Financials and Metrics

Roche Revenue

Roche's revenue was reported to be CHF62.8 b in FY, 2021
CHF

Revenue (FY, 2021)

62.8b

Gross profit (FY, 2021)

50.4b

Net income (FY, 2021)

14.9b

EBITDA (FY, 2021)

23.2b

EBIT (FY, 2021)

18.2b

Market capitalization (29-Jun-2022)

277.1b

Closing stock price (29-Jun-2022)

319.6

Cash (31-Dec-2021)

6.9b

EV

302.8b
Roche's current market capitalization is CHF277.1 b.
Annual
CHFFY, 2019FY, 2020FY, 2021

Revenue

61.5b58.3b62.8b

Cost of goods sold

(12.0b)(12.0b)(15.5b)

Gross profit

51.7b48.3b50.4b

R&D expense

(12.8b)(12.3b)(13.9b)
Half Year
CHFH1, 2019H1, 2020H1, 2021

Revenue

30.5b29.3b30.7b

Cost of goods sold

(6.2b)(5.2b)(6.7b)

Gross profit

25.5b25.1b25.4b

R&D expense

(6.1b)(6.3b)(7.1b)
Annual
CHFFY, 2018FY, 2019FY, 2020FY, 2021

Cash

6.7b6.1b5.7b6.9b

Accounts Receivable

9.8b10.4b10.2b10.8b

Prepaid Expenses

891.0m1.0b1.3b2.2b

Inventories

6.6b6.1b7.2b7.7b
Half Year
CHFH1, 2019H1, 2020H1, 2021

Cash

5.7b3.8b5.0b

Accounts Receivable

11.8b11.7b11.7b

Prepaid Expenses

191.0m189.0m153.0m

Inventories

6.6b6.8b8.3b
Annual
CHFFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

10.9b14.1b15.1b14.9b

Depreciation and Amortization

3.6b3.9b4.2b4.1b
Half Year
CHFH1, 2019H1, 2020H1, 2021

Net Income

8.9b8.5b8.2b

Depreciation and Amortization

2.1b2.0b2.1b
Show all financial metrics

Roche Operating Metrics

Roche's Patients was reported to be 28.9 m in FY, 2020.
FY, 2018FY, 2019FY, 2020

Patients

127 m63.18 m28.87 m

Patients Treated with Off-Patent Medicines

124 m61.48 m26.58 m

Patients Treated with Patent Medicines

3 m1.7 m2.29 m

Tests Conducted (Diagnostics Products)

20 b21.4 b23.4 b

Roche Acquisitions / Subsidiaries

Company NameDateDeal Size
TIB Molbiol GroupDecember 01, 2021
GenMark DiagnosticsApril 22, 2021$1.9 b
InflazomeSeptember 21, 2020$449 m
Stratos GenomicsMay 22, 2020
PromediorNovember 15, 2019$1.4 b
Spark TherapeuticsFebruary 25, 2019$4.8 b
Tusk TherapeuticsSeptember 28, 2018
Flatiron HealthFebruary 15, 2018$1.9 b
IgnytaDecember 22, 2017$1.7 b
ViewicsNovember 17, 2017
Show more

Roche Revenue Breakdown

Embed Graph

Roche revenue breakdown by business segment: 71.7% from PHARMACEUTICALS and 28.3% from DIAGNOSTICS

Human Capital Metrics

Embed Graph

Roche Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Roche Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Roche Online and Social Media Presence

Embed Graph

Roche Company Culture

  • Overall Culture

    A-

    75/100

  • CEO Rating

    A+

    82/100

  • Compensation

    B+

    74/100

  • Diversity

    C-

    61/100

Learn more on Comparably

Roche News and Updates

Insights on the Smart Medical Devices Global Market to 2026 - Featuring Abbott, Biotronik, Boston Scientific and F. Hoffmann-La Roche Among Others

DUBLIN, June 30, 2022 /PRNewswire/ -- The "Smart Medical Devices: Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global market for smart medical devices reached $56.4 billion in 2021 and should reach more than $122.8 billion in 2026, with a...

Global Histology and Cytology IVD Market Report 2021-2022 & 2026 with Competitive Analysis of Agilent, Danaher, Hologic, Illumina, & Roche

DUBLIN, June 30, 2022 /PRNewswire/ -- The "Histology and Cytology IVD Market Update" report has been added to ResearchAndMarkets.com's offering. This report, Histology and Cytology IVD Market Update, provides competitive analysis of the histology/cytology market from 2021 to 2026....

Roche launches new BenchMark ULTRA PLUS system for cancer diagnostics enabling timely, targeted patient care

Basel, 29 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the BenchMark ULTRA PLUS system, its newest advanced tissue staining platform. The system enables quick and accurate test results so clinicians can make timely decisions regarding a patient’s care journey.

Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics

Basel, 28 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE launch of the next-generation VENTANA DP 600 slide scanner (CE-IVD marked). This high-capacity slide scanner produces excellent image quality of stained histology slides from patient tissue samples, while providing ease-…

Global $223.21 Billion Oncology Drugs Markets to 2031 with F.Hoffmann-La Roche, Novartis, Gilead Sciences, Bayer and Takeda Pharmacueticals Dominating

Dublin, June 21, 2022 (GLOBE NEWSWIRE) -- The "Oncology Drugs Global Market Report 2022, By Type, Drug Type, Drug Classification" report has been added to ResearchAndMarkets.com's offering.

Global Therapeutic Proteins Market Report 2022-2031 Featuring Major Players - Abbott Laboratories; Amgen Inc.; Baxter International Inc.; Eli Lilly and Company; F.Hoffmann-La Roche

DUBLIN, June 20, 2022 /PRNewswire/ -- The "Therapeutic Proteins Global Market Report 2022: By Product, By Application, By Function" report has been added to ResearchAndMarkets.com's offering. The global therapeutic proteins market is expected to grow from $100.06 billion in 2021 to...
Show more

Roche Frequently Asked Questions

  • When was Roche founded?

    Roche was founded in 1896.

  • Who are Roche key executives?

    Roche's key executives are Severin Schwan, William N. Anderson and Thomas Schinecker.

  • How many employees does Roche have?

    Roche has 100,920 employees.

  • What is Roche revenue?

    Latest Roche annual revenue is CHF62.8 b.

  • What is Roche revenue per employee?

    Latest Roche revenue per employee is CHF622.3 k.

  • Who are Roche competitors?

    Competitors of Roche include Thermo Fisher Scientific, Leica Biosystems and Dexcom.

  • Where is Roche headquarters?

    Roche headquarters is located at 124 Grenzacherstrasse, Basel.

  • Where are Roche offices?

    Roche has offices in Basel, Risch-Rotkreuz, Rotkreuz ZG, Schlieren and in 113 other locations.

  • How many offices does Roche have?

    Roche has 147 offices.